 David Higgins
Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis B | 3 | 2023 | 51 | 2.490 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2023 | 285 | 1.330 |
Why?
| | Hepatitis B Vaccines | 1 | 2023 | 46 | 0.840 |
Why?
| | Sexual Health | 1 | 2023 | 46 | 0.820 |
Why?
| | Chlamydia Infections | 1 | 2023 | 63 | 0.810 |
Why?
| | Gonorrhea | 1 | 2023 | 54 | 0.810 |
Why?
| | Sexually Transmitted Diseases | 1 | 2023 | 154 | 0.750 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2023 | 179 | 0.740 |
Why?
| | Sexual and Gender Minorities | 1 | 2023 | 138 | 0.710 |
Why?
| | HIV Infections | 2 | 2023 | 2453 | 0.650 |
Why?
| | Vaccines | 1 | 2023 | 375 | 0.620 |
Why?
| | Anti-HIV Agents | 1 | 2023 | 663 | 0.570 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2017 | 53 | 0.550 |
Why?
| | Mycobacterium tuberculosis | 5 | 2010 | 269 | 0.500 |
Why?
| | Telemedicine | 1 | 2023 | 662 | 0.500 |
Why?
| | Ventricular Function, Left | 2 | 2017 | 477 | 0.490 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2017 | 350 | 0.460 |
Why?
| | Tuberculosis, Pulmonary | 3 | 2010 | 113 | 0.450 |
Why?
| | Hepatitis B Surface Antigens | 2 | 2023 | 18 | 0.440 |
Why?
| | Heart Ventricles | 1 | 2017 | 723 | 0.400 |
Why?
| | Interleukin-10 | 3 | 2014 | 293 | 0.380 |
Why?
| | Vaccination | 3 | 2023 | 1202 | 0.370 |
Why?
| | Vitamin D Deficiency | 1 | 2012 | 158 | 0.340 |
Why?
| | Cross Infection | 1 | 2012 | 194 | 0.340 |
Why?
| | Foreign-Body Reaction | 1 | 2009 | 22 | 0.330 |
Why?
| | Implants, Experimental | 1 | 2009 | 18 | 0.330 |
Why?
| | Tuberculosis | 3 | 2010 | 241 | 0.320 |
Why?
| | Vitamin D | 1 | 2012 | 340 | 0.320 |
Why?
| | Macrophage Colony-Stimulating Factor | 1 | 2008 | 17 | 0.300 |
Why?
| | Intensive Care Units | 1 | 2012 | 614 | 0.290 |
Why?
| | Length of Stay | 1 | 2012 | 957 | 0.290 |
Why?
| | Pregnancy | 3 | 2023 | 5499 | 0.290 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 140 | 0.290 |
Why?
| | Critical Illness | 1 | 2012 | 640 | 0.280 |
Why?
| | Mass Screening | 2 | 2023 | 979 | 0.270 |
Why?
| | Pandemics | 2 | 2023 | 1310 | 0.250 |
Why?
| | Biocompatible Materials | 1 | 2009 | 372 | 0.250 |
Why?
| | Heart Failure | 1 | 2017 | 1958 | 0.240 |
Why?
| | Female | 13 | 2023 | 59325 | 0.230 |
Why?
| | Blood Coagulation Tests | 1 | 2023 | 51 | 0.220 |
Why?
| | Hepatitis B virus | 1 | 2023 | 25 | 0.210 |
Why?
| | Mitral Valve Insufficiency | 1 | 2023 | 69 | 0.210 |
Why?
| | Infant, Newborn | 2 | 2023 | 5038 | 0.200 |
Why?
| | Humans | 15 | 2023 | 114043 | 0.200 |
Why?
| | Homosexuality, Male | 1 | 2023 | 169 | 0.200 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2014 | 57 | 0.200 |
Why?
| | HIV | 1 | 2023 | 208 | 0.200 |
Why?
| | Retrospective Studies | 4 | 2023 | 12521 | 0.190 |
Why?
| | Infectious Disease Transmission, Vertical | 1 | 2023 | 150 | 0.190 |
Why?
| | Macrophages | 1 | 2008 | 1259 | 0.190 |
Why?
| | Disease Progression | 3 | 2017 | 2371 | 0.180 |
Why?
| | Pneumonia, Aspiration | 2 | 2013 | 15 | 0.170 |
Why?
| | Stroke Volume | 2 | 2023 | 513 | 0.160 |
Why?
| | Genomics | 1 | 2023 | 633 | 0.160 |
Why?
| | Hospitals | 1 | 2023 | 581 | 0.150 |
Why?
| | Chemokines, C | 2 | 2008 | 2 | 0.150 |
Why?
| | Deglutition Disorders | 2 | 2013 | 117 | 0.150 |
Why?
| | RNA, Small Interfering | 2 | 2010 | 534 | 0.140 |
Why?
| | Antiviral Agents | 1 | 2023 | 642 | 0.140 |
Why?
| | Ferritins | 1 | 2017 | 52 | 0.140 |
Why?
| | Lung | 5 | 2013 | 3521 | 0.130 |
Why?
| | Transforming Growth Factor beta | 2 | 2009 | 445 | 0.130 |
Why?
| | Iron | 1 | 2017 | 232 | 0.130 |
Why?
| | Tracheostomy | 1 | 1997 | 97 | 0.130 |
Why?
| | Parents | 1 | 2023 | 1181 | 0.130 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2023 | 1168 | 0.120 |
Why?
| | Mice | 9 | 2014 | 14841 | 0.120 |
Why?
| | Brain Neoplasms | 1 | 2022 | 966 | 0.120 |
Why?
| | Child | 4 | 2023 | 18400 | 0.120 |
Why?
| | Cytokines | 4 | 2010 | 1824 | 0.120 |
Why?
| | Echocardiography | 1 | 2017 | 569 | 0.120 |
Why?
| | Th1 Cells | 3 | 2010 | 123 | 0.110 |
Why?
| | Heme Oxygenase (Decyclizing) | 1 | 2013 | 21 | 0.110 |
Why?
| | Propranolol | 1 | 2013 | 46 | 0.110 |
Why?
| | Biomarkers | 2 | 2017 | 3397 | 0.110 |
Why?
| | Sialorrhea | 1 | 2013 | 1 | 0.110 |
Why?
| | Interferon-gamma | 4 | 2010 | 719 | 0.110 |
Why?
| | Critical Care | 1 | 1997 | 472 | 0.110 |
Why?
| | Neuromuscular Agents | 1 | 2013 | 30 | 0.100 |
Why?
| | Metabolic Diseases | 1 | 2013 | 98 | 0.100 |
Why?
| | Botulinum Toxins, Type A | 1 | 2013 | 40 | 0.100 |
Why?
| | Quality of Life | 1 | 2022 | 2343 | 0.100 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2008 | 959 | 0.100 |
Why?
| | Male | 7 | 2023 | 55396 | 0.100 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2013 | 286 | 0.090 |
Why?
| | Confidence Intervals | 1 | 2012 | 302 | 0.090 |
Why?
| | Animals | 11 | 2014 | 31565 | 0.090 |
Why?
| | Follow-Up Studies | 2 | 2017 | 4392 | 0.090 |
Why?
| | Pulmonary Fibrosis | 1 | 2014 | 321 | 0.090 |
Why?
| | Macrophages, Alveolar | 2 | 2014 | 348 | 0.090 |
Why?
| | Lymphocyte Activation | 3 | 2010 | 1036 | 0.090 |
Why?
| | Patient Admission | 1 | 2012 | 175 | 0.090 |
Why?
| | Neoplasms | 1 | 2023 | 2086 | 0.090 |
Why?
| | Hemorrhage | 1 | 2014 | 600 | 0.090 |
Why?
| | Cause of Death | 1 | 2012 | 362 | 0.090 |
Why?
| | Infant | 1 | 2023 | 7943 | 0.090 |
Why?
| | Risk Factors | 1 | 2023 | 8614 | 0.090 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2010 | 153 | 0.080 |
Why?
| | Prognosis | 1 | 2017 | 3315 | 0.080 |
Why?
| | Proportional Hazards Models | 1 | 2012 | 1078 | 0.080 |
Why?
| | Bone Marrow Cells | 1 | 2010 | 266 | 0.080 |
Why?
| | Oximetry | 1 | 2009 | 79 | 0.080 |
Why?
| | Lymphocyte Subsets | 1 | 2009 | 79 | 0.080 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2008 | 41 | 0.080 |
Why?
| | Chronic Disease | 3 | 2010 | 1577 | 0.080 |
Why?
| | Immunohistochemistry | 2 | 2009 | 1624 | 0.080 |
Why?
| | Flow Cytometry | 2 | 2009 | 1075 | 0.080 |
Why?
| | Mice, Inbred C57BL | 4 | 2010 | 4680 | 0.070 |
Why?
| | Sepsis | 1 | 2013 | 507 | 0.070 |
Why?
| | Cell Count | 1 | 2008 | 303 | 0.070 |
Why?
| | United States | 1 | 2023 | 12137 | 0.070 |
Why?
| | Monocytes | 1 | 2010 | 503 | 0.070 |
Why?
| | Granuloma | 1 | 2007 | 82 | 0.070 |
Why?
| | Adult | 3 | 2023 | 30375 | 0.070 |
Why?
| | Immune Tolerance | 1 | 2009 | 321 | 0.070 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2007 | 154 | 0.070 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2008 | 350 | 0.070 |
Why?
| | Mice, Knockout | 2 | 2010 | 2562 | 0.070 |
Why?
| | Patient Discharge | 1 | 2012 | 770 | 0.070 |
Why?
| | Prevalence | 1 | 2012 | 2247 | 0.060 |
Why?
| | Fibrosis | 2 | 2023 | 452 | 0.060 |
Why?
| | Dendritic Cells | 1 | 2008 | 435 | 0.060 |
Why?
| | Pneumonia | 1 | 2010 | 563 | 0.060 |
Why?
| | Lung Diseases, Interstitial | 1 | 2009 | 495 | 0.060 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 1690 | 0.050 |
Why?
| | Cells, Cultured | 2 | 2008 | 3861 | 0.050 |
Why?
| | Mitral Valve | 1 | 2023 | 94 | 0.050 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2007 | 686 | 0.050 |
Why?
| | Cardiac Volume | 1 | 2001 | 11 | 0.050 |
Why?
| | Treatment Outcome | 2 | 2013 | 9049 | 0.050 |
Why?
| | Ventricular Function, Right | 1 | 2023 | 256 | 0.050 |
Why?
| | Prospective Studies | 1 | 2012 | 6195 | 0.050 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2001 | 172 | 0.040 |
Why?
| | Phenotype | 1 | 2008 | 2784 | 0.040 |
Why?
| | Precision Medicine | 1 | 2023 | 335 | 0.040 |
Why?
| | Aged | 2 | 2012 | 18969 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2023 | 1791 | 0.040 |
Why?
| | Monitoring, Physiologic | 1 | 1997 | 248 | 0.030 |
Why?
| | Hemosiderin | 1 | 2014 | 2 | 0.030 |
Why?
| | Bleeding Time | 1 | 2014 | 6 | 0.030 |
Why?
| | Fibrin | 1 | 2014 | 63 | 0.030 |
Why?
| | Enzyme Induction | 1 | 2013 | 83 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2014 | 398 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 1997 | 1331 | 0.030 |
Why?
| | Myofibroblasts | 1 | 2014 | 115 | 0.030 |
Why?
| | Disease Models, Animal | 2 | 2014 | 3498 | 0.030 |
Why?
| | Patient Care Team | 1 | 1997 | 517 | 0.030 |
Why?
| | Intubation, Gastrointestinal | 1 | 2013 | 54 | 0.030 |
Why?
| | Movement Disorders | 1 | 2013 | 48 | 0.030 |
Why?
| | Injections | 1 | 2013 | 160 | 0.030 |
Why?
| | Middle Aged | 1 | 2012 | 26605 | 0.020 |
Why?
| | Ultrasonography, Interventional | 1 | 2013 | 120 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 714 | 0.020 |
Why?
| | Butylated Hydroxytoluene | 1 | 2010 | 31 | 0.020 |
Why?
| | Infrared Rays | 1 | 2009 | 20 | 0.020 |
Why?
| | Survival Rate | 1 | 2013 | 1638 | 0.020 |
Why?
| | Interleukin-4 | 1 | 2010 | 204 | 0.020 |
Why?
| | Cell Polarity | 1 | 2010 | 131 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 2013 | 571 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2009 | 271 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2182 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2008 | 285 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2009 | 217 | 0.020 |
Why?
| | Gene Silencing | 1 | 2008 | 171 | 0.020 |
Why?
| | Aerosols | 1 | 2008 | 150 | 0.020 |
Why?
| | Sex Factors | 1 | 2013 | 1706 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2008 | 637 | 0.020 |
Why?
| | Rats | 1 | 2013 | 4913 | 0.020 |
Why?
| | Oxygen | 1 | 2009 | 851 | 0.010 |
Why?
| | Hospitalization | 1 | 2013 | 1762 | 0.010 |
Why?
| | Cohort Studies | 1 | 2013 | 4883 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2008 | 1735 | 0.010 |
Why?
| | Phantoms, Imaging | 1 | 2001 | 123 | 0.010 |
Why?
| | Observer Variation | 1 | 2001 | 298 | 0.010 |
Why?
| | Swine | 1 | 2001 | 687 | 0.010 |
Why?
|
|
Higgins's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|